تقييم مستويات جلوبيولني املناعي A املفرز يف اللعاب لدى مرضى السكري وعالقته مع أعراض الفم واألسنان �سهال كاكوي، بهاره ح�سيني، علي اأكرب حاجدو�ست، مويجن �سنجاري، اأحمد غالم ح�سينيان ، وحيد اف�سار abstract: Objectives: Oral and dental manifestations in diabetic patients can arise due to numerous factors, including elevated salivary secretory immunoglobulin A (s-IgA) levels. This study aimed to evaluate s-IgA concentrations in patients with type 2 diabetes mellitus (T2DM) and to investigate the association between s-IgA levels and oral and dental manifestations of T2DM. Methods: This cross-sectional descriptive study was carried out between October 2011 and September 2012 in Kerman, Iran, and included 260 subjects (128 patients with T2DM and 132 healthy controls). Unstimulated salivary samples were collected from all subjects and s-IgA levels were determined using the immunoturbidimetric method. The oral cavities and teeth of T2DM patients were evaluated for oral and dental manifestations. Results: Both diabetic and control subjects with higher concentrations of s-IgA had significantly higher numbers of decayed, missing or filled teeth (DMFT) and periodontal index (PDI) scores (P <0.050). s-IgA levels were significantly higher in subjects with oral candidiasis (P <0.050). Among diabetic patients, significantly higher s-IgA levels were concomitant with xerostomia and denture stomatitis (P ≤0.050). There were no significant differences between s-IgA concentrations and other oral or dental manifestations in either group. Conclusion: Individuals with a greater number of DMFT, a higher PDI score and oral candidiasis had significantly higher s-IgA levels. s-IgA levels were not significantly higher among diabetic patients in comparison to the control group. However, significantly higher s-IgA levels occurred with xerostomia and denture stomatitis in diabetic patients. In addition, s-IgA was significantly higher in patients with uncontrolled diabetes compared to those with controlled diabetes. Keywords: Diabetes Mellitus; Saliva; Secretory Immunoglobulin A; Oral Manifestations; Iran. امللخ�ص: الهدف: اأعرا�ض الفم والأ�سنان يف مر�سى ال�سكري ميكن اأن تن�ساأ نتيجة لعوامل عديدة، مبا يف ذلك ارتفاع م�ستويات جلوبيولني املناعي A املفرز يف اللعاب. هدفت هذه الدرا�سة اإىل تقييم تركيز جلوبيولني املناعي A املفرز يف لعاب املر�سى الذين يعانون من النوع 2 من داء ال�سكري ولتقييم ارتباط م�ستويات جلوبيولني املناعي A املفرز واأعرا�ض الفم والأ�سنان. الطريقة: اأجريت هذه الدرا�سة الو�سفية من و 132 النوع 2 من ال�سكري مر�سى من 128( �سخ�سا و�سملت 260 اإيران، كرمان، يف و�سبتمرب 2012 اأكتوبر 2011 بني امل�ستعر�سة ال�سحاء(. مت جمع عينات اللعاب غرياملحفز من جميع امل�ساركني ومت حتديد م�ستويات جلوبيولني املناعي A با�ستخدام طريقة قيا�ض التعكر املناعي. مت تقييم جتاويف الأ�سنان والفم ملر�سى ال�سكري. النتائج: كان ال�سحاء ومر�سى ال�سكري الذين لديهم تركيزات اأعلى من م�ستويات جلوبيولني املناعي A لديهم ن�سبة اأعلى اإح�سائيا من الأ�سنان النخرة واملفقودة اأو بها ح�سو اأ�سنان ودرجات موؤ�رس اللثة اأعلى )P >0.050(. وكانت م�ستويات جلوبيولني املناعي A اأعلى بكثري يف امل�ساركني الذين لديهم داء املبي�سات الفموي )P >0.050(. ويف مر�سى .)P ≤0.050( املرتفعة اإح�سائيا م�ساحبة جلفاف الفم والتهاب الفم امل�ساحب لطقم الأ�سنان A ال�سكري، كانت م�ستويات جلوبيولني املناعي مل توجد فروق اخرى ذات دللة اإح�سائية بني م�ستويات جلوبيولني املناعي A و اأعرا�ض الفم اأو الأ�سنان يف اأي من املجموعتني )ال�سكري والأ�سحاء(. اخلال�صة: ال�سخا�ض الذين لديهم اأ�سنان نخرة اأومفقودة اأو بها ح�سو اأ�سنان ودرجات موؤ�رس اللثة مرتفعة ولديهم داء املبي�سات الفموي لديهم ن�سبة اأعلى بكثري يف م�ستويات جلوبيولني املناعي A. ولكن لي�ض هناك فرق اإح�سائي يف م�ستويات جلوبيولني املناعي A املناعي جلوبيولني م�ستويات يف اإح�سائية زيادة فهناك ذلك، ومع الأ�سحاء. التحكم جمموعة مع مقارنة ال�سكري مر�سى لدى A عند الأ�سخا�ض امل�سابني بجفاف الفم والتهاب الفم امل�ساحب لطقم الأ�سنان يف مر�سى ال�سكري. بالإ�سافة اإىل ذلك، فاإن التهاب الفم امل�ساحب لطقم الأ�سنان اأعلى بكثري يف املر�سى الذين يعانون من مر�ض ال�سكري غري املن�سبط مقارنة مع اأولئك امل�سابني بداء ال�سكري املن�سبط بالعالج. مفتاح الكلمات: مر�ض ال�سكري؛ اللعاب؛ جلوبيولني املناعي A؛ اأعرا�ض الفم؛ اإيران. Evaluation of Salivary Secretory Immunoglobulin A Levels in Diabetic Patients and Association with Oral and Dental Manifestations Shahla Kakoei,1,2 *Bahareh Hosseini,1,3 Ali-Akbar Haghdoost,4 Mojgan Sanjari,5 Ahmad Gholamhosseinian,6 Vahid F. N. Afshar2 Departments of 1Oral Medicine and 6Biochemistry and Centers for 2Oral & Dental Diseases Research, 3Endontology Research, 4Modeling in Health Research and 5Endocrinology & Metabolism Diseases Research, Institute of Basic & Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran *Corresponding Author e-mail: bhd_1362@yahoo.com clinical & basic research Sultan Qaboos University Med J, November 2015, Vol. 15, Iss. 4, pp. e507–511, Epub. 23 Nov 15 Submitted 28 Dec 14 Revisions Req. 10 Mar & 6 May 15; Revisions Recd. 13 Apr & 19 May 15 Accepted 24 May 15 doi: 10.18295/squmj.2015.15.04.011 Evaluation of Salivary Secretory Immunoglobulin A Levels in Diabetic Patients and Association with Oral and Dental Manifestations e508 | SQU Medical Journal, November 2015, Volume 15, Issue 4 Advances in Knowledge - To the best of the authors’ knowledge, little information exists regarding the probable association between salivary secretory immunoglobulin A (s-IgA) levels and oral and dental manifestations in patients with type 2 diabetes (T2DM). Advances in Patient Care - Determination of the salivary components of patients with T2DM could play a fundamental role in predicting, detecting and managing oral and dental manifestations of the disease. Based on the results of this study, it is recommended that patients exhibiting a change or decrease in their s-IgA levels undergo periodic oral health evaluations. Type 2 diabetes mellitus (t2dm) is one of the most prevalent metabolic disorders worldwide; by 2025, approximately 320 million people will have the disease.1 The disease has a wide range of signs and symptoms and manifests differently in various organs. In the oral cavity, manifestations of diabetes can include a dry or burning mouth, periodontal diseases, bone loss, dental abscesses, fungal and bacterial infections, oral lichen planus and delayed wound healing.1,2 Immunoglobulin A (IgA) and immunoglobulin G affect oral cavity microorganisms in the saliva, gingival sulcular fluid and plasma.3 These antibodies prevent bacterial metabolism and adhesion of microorganisms to the oral tissue.3 Although there are many non- specific defensive elements in the saliva, such as lactoferrin and lysozymes, salivary secretory IgA (s-IgA) is the foremost protective mechanism against bacterial colonisation of the oral mucous membranes. As s-IgA plays an important role in protecting against these pathogens, the antibody might also protect against periodontal diseases.4 Changes in salivary IgA concentrations in diabetic patients could have an effect on their oral health. Several studies have sought to determine salivary flow rates and components that can affect the progression, symptoms and varieties of oral changes in diabetic patients.1,2,5 Overall, determining the salivary components of diabetic patients can be useful in detecting and managing their oral manifestations.5 Previous research has assessed s-IgA levels and oral conditions among diabetic patients. A Brazilian study reported that diabetic patients with lower s-IgA levels had more severe and frequent periodontal disease.4 However, two Iranian studies yielded different results: Mohiti-Ardekani et al. recorded significantly higher s-IgA levels in diabetic patients while Bakianian Vaziri et al. found no significant differences between diabetic and non-diabetic groups.1,5 Other studies have also reported conflicting results with regards to s-IgA levels and their relationship to various diseases.6,7 The current study aimed to compare s-IgA levels between healthy subjects and T2DM patients and determine the association between s-IgA levels and various oral and dental manifestations in diabetic patients. This relationship could help determine the prognosis of oral diseases in diabetic patients and serve as a guide for their dental care. Methods This cross-sectional descriptive study was carried out between October 2011 and September 2012 in Kerman, Iran, and included 260 subjects divided into two groups. The first group consisted of 128 patients with T2DM who routinely attended follow- up appointments at the Diabetes Center of Shahid Bahonar Hospital in Kerman. The non-diabetic control group was composed of 132 healthy individuals with no history of DM who attended annual check-ups at either the Razi Laboratory or the Besat Clinical Laboratory in Kerman. Information regarding the subjects’ gender, age, diabetes type and medical results (including assessments of glycated haemoglobin [HbA1C] and fasting blood sugar [FBS] levels) was compiled by a trained dental student. Smokers and subjects <20 years old were excluded from the study. Control subjects were included only if they had FBS levels of <100 mg/dL, no systemic disorders and did not take medications that affected either IgA secretion or its levels in the saliva. A diagnosis of T2DM was made with a HbA1C level of ≥6.5%, fasting plasma glucose (PG) level of ≥126 mg/dL and a two-hour PG level of ≥200 mg/dL. For patients exhibiting classic symptoms of hyperglycaemic crises, a random PG measurement of ≥200 mg/dL met the criteria for a diagnosis of T2DM.8 Known diabetic patients who were already taking medicine for lowering blood glucose and who had a HbA1C level of ≥6.5% were determined to have uncontrolled T2DM. The oral mucosa of all subjects was checked for abnormalities, including manifestations of oral candidiasis (erythematous candidiasis, thrush, angu- lar cheilitis, median rhomboid glossitis and denture stomatitis), lichenoid reactions and frequent abs- cesses. The characteristics of any noted lesions and their locations were recorded. In addition, a tongue blade test was performed on all participants to detect xerostomia. The guidelines of the World Health Organization for assessing dental cavities were used to calculate the number of decayed, missing or filled teeth (DMFT).9 The periodontal disease index (PDI) were used to evaluate the effect of any periodontal disease on the supporting tissues of the oral mucosa. Xerostomia was assessed using Fox et al.’s standardised questionnaire.10 Shahla Kakoei, Bahareh Hosseini, Ali-Akbar Haghdoost, Mojgan Sanjari, Ahmad Gholamhosseinian and Vahid F. N. Afshar Clinical and Basic Research | e509 Unstimulated salivary samples were collected from all subjects in the morning (between 7:30 and 9:30 a.m.) after fasting for eight hours and having cleaned their mouths and teeth 90 minutes beforehand.1 Participants were requested to keep their mouths closed for a few moments in order for saliva to pool and then hold their heads over a container and release, resulting in a sample of 1‒2 mL of saliva.3 Samples were then frozen to -20 °C and sent to a laboratory for testing.11 Concentrations of s-IgA were determined using the immunoturbidimetric method with measurements obtained from a commercial kit (Pars Azmoon Co., Tehran, Iran) and an automated continuous flow analyser (AutoAnalyzer, TechniCon Systems Inc., Oakland, California, USA).12 Data were analysed using the Statistical Package for the Social Sciences (SPSS), Version 17 (IBM Corp., Chicago, Illinois, USA). Pearson’s correlation coefficient test was used to determine the relationship between s-IgA levels and age, HbA1C and FBS. The independent t-test was used to compare DMFT and PDI indices between the groups. This study was approved by the Ethics Committee of Kerman University of Medical Sciences (#K/91/05). All subjects gave informed consent before participating in the study. Results A total of 128 T2DM patients and 132 healthy adults were included in the study. The mean age of the subjects was 47.96 years (range: 20–83 years old). Mean s-IgA levels in the diabetic and control groups were 45.40 ± 6.87 mg/dL and 41.17 ± 7.66 mg/dL, respectively; this difference between the two groups was not significant (P >0.050). There was no significant difference in s-IgA levels between genders or with age. However, there was a significant increase in s-IgA levels among patients with uncontrolled T2DM compared to those with controlled disease (P <0.050). Both the DMFT and PDI indices showed significant increases among the diabetic patients in comparison with the control group (P <0.050). Between the two groups, s-IgA levels were significantly higher among subjects with a higher PDI index. Correlations between s-IgA levels and other variables are shown in Table 1. Table 2 shows the distribution of various oral and dental manifestations among the two groups. s-IgA levels were significantly higher in subjects with oral candidiasis in both the diabetic and control groups. Tongue blade signs were positive for two subjects in the control group and 38 patients in the diabetic group. s-IgA levels were significantly higher for diabetic patients with xerostomia in comparison to the control subjects (P = 0.050). Diabetic patients also suffered from denture stomatitis more frequently than control subjects with significantly higher s-IgA levels (P ≤0.050). Discussion As patients with systemic diseases such as DM become better educated regarding self-management Table 1: Correlation between salivary secretory immunoglobulin A concentrations and other variables among control and diabetic subjects in Kerman, Iran (N = 260) Variable Correlation with s-IgA concentration r (P value) Control group (n = 132) Diabetic group (n = 128) Total Age 0.05 (0.520) 0.15 (0.070) 0.10 (0.080) HbA1C - 0.30 (0.009)* - FBS -0.07 (0.370) -0.06 (0.460) -0.01 (0.830) DMFT 0.06 (0.510) 0.22 (0.040)† 0.14 (0.04)† PDI 0.40 (0.001)* 0.50 (0.004)* 0.12 (0.001)* s-IgA = salivary secretory immunoglobulin A; HbA1C = glycated haemoglobin; FBS = fasting blood sugar; DMFT = decayed, missing or filled teeth; PDI = periodontal index. *Highly statistically significant at P <0.001. †Statistically significant at P <0.050. Table 2: Comparison between salivary secretory immunoglobulin A levels and oral and dental manifestations among control and diabetic subjects in Kerman, Iran (N = 260) Oral/dental manifestation Control group Diabetic group Mean IgA in mg/dL ± SE P value Mean IgA in mg/dL ± SE P value Oral candidiasis 79.5 ± 16.5 0.010* 67.5 ± 10.6 0.006* Erythematous candidiasis - - 74.0 ± 16.8 0.160 Thrush - - 49.0 ± 11.7 0.630 Median rhomboid glossitis - - 35.7 ± 15.9 0.810 Denture stomatitis 64.1 ± 22.9 0.280 71.4 ± 14.7 0.002 Angular cheilitis 95.0 ± 25.0 0.010* 89.2 ± 27.9 0.110 Lichenoid reactions 34.6 ± 6.6 0.880 126.5 ± 76.5 0.460 Frequent abscesses - - 35.0 ± 6.5 0.650 Xerostomia 35.0 ± 15.0 0.890 51.8 ± 7.5 0.050* IgA = immunoglobulin A; SE = standard error. *Statistically significant at P ≤0.05. Evaluation of Salivary Secretory Immunoglobulin A Levels in Diabetic Patients and Association with Oral and Dental Manifestations e510 | SQU Medical Journal, November 2015, Volume 15, Issue 4 and beneficial lifestyle choices, they are increasingly seeking to address their oral health issues.13 While various research has focused on diabetic subjects, few studies have evaluated salivary immunoglobulin levels among this patient population. Unlike other body fluids, saliva is easily accessible and there is therefore no need for aggressive sampling techniques in order to make a diagnosis or determine the prognosis of a disease. As such, many researchers prefer to use saliva instead of blood for sampling purposes.14,15 Saliva is a complex biological fluid and conditions which affect saliva production—such as xerostomia and saliva excretion dysfunction—decrease its buffering and cleansing capacity. In addition, neuropathic disturbances in diabetic patients can influence the development of dental caries and periodontal diseases.16 Within the oral cavity, s-IgA can act as the first line of defence against pathogens that affect mucous membranes by preventing the aggregation and adhesion of bacteria to the mucosa and neutralising enzymes, toxins and viruses.10 The concentrations of various salivary elements, such as s-IgA, have been investigated in a number of systemic diseases as well as many oral conditions, including periodontitis, xerostomia, lichen planus and smoking-induced oral diseases.14,17–21 Immune suppression or disturbances have been observed in diabetic patients;2 it is possible that T2DM affects the secretion of IgA in the saliva and, consequently, the defence reaction of the mucosa. In the present study, s-IgA levels in diabetic patients were not significantly higher in comparison with non-diabetic individuals. This result is similar to those seen in previous studies.5–7,9,22 In contrast, Mohiti-Ardekani et al. demonstrated that s-IgA levels in diabetic patients were higher than in non-diabetics.1 Other studies have also found higher s-IgA levels in diabetic patients.1,22 Discrepancies between these results could be attributed to differences in study designs and sampling and measuring techniques (e.g. the use of stimulated versus unstimulated saliva or immunoturbidimetric versus immunonephelometric methods).5 s-IgA levels were considerably higher in patients with uncontrolled T2DM in the current study. Harrison et al. and Malicka et al. found similarly high s-IgA levels in patients with poorly controlled diabetes.10,24 In the current research, there was a significant positive relationship between s-IgA and PDI and DMFT indices in both groups, suggesting that the innate immune system tries to synthesise high levels of IgA to reduce periodontal tissue infections.10 In addition, Kakoei et al. also noted a positive association between high salivary glucose levels and DMFT and PDI indices in diabetic patients.25 This is compatible with other findings showing that s-IgA levels were significantly higher in diabetic patients with periodontitis.10,18,26 Using the gingival and modified sulcus bleeding indices, Malicka et al. reported that the periodontal status of diabetic patients was significantly worse than that of healthy subjects.12 Ranadheer et al. showed that s-IgA levels were significantly higher among individuals with more than three DMFT.15 In studies by Bakianian Vaziri et al. and Lopez et al., diabetic patients had significantly increased numbers of DMFT in comparison with healthy subjects.5,27 In the current study, the prevalence of oral candidiasis was significantly higher in the subjects with higher s-IgA levels in both groups; this is consistent with the results observed by Jaganathan et al.28 However, no significant relationship between s-IgA and oral lichen planus was found. This correlates with previous research by Divya et al., who did not report any significant association between s-IgA levels and pre-cancerous lesions like lichen planus.20 In contrast, Ghalayani et al. found higher s-IgA levels in patients with oral lichen planus in comparison with normal individuals.21 In the present study, a significant increase in s-IgA levels was found in diabetic patients with denture stomatitis. A study by Papova et al. also showed that s-IgA levels in patients with denture stomatitis were significantly higher in comparison to a control group.29 The results of the current study differed from those observed in a study by Wilson et al., who found that that s-IgA levels were significantly lower in denture wearers with denture stomatitis in comparison to healthy subjects.30 Changes in the function and components of saliva as a result of different conditions among diabetic patients (e.g. dental caries, periodontitis, burning mouth and sensory problems) are not yet fully understood. Previous investigations have shown the efficacy of the buffering capacity and cleansing effect of saliva in negating some of these changes.16 However, the differences in s-IgA levels in different studies could be attributed to different sampling techniques or detection methods. One of the limitations of the current study was an inability to assess oral hygiene among the subjects. Further investigations are recommended to detect salivary immunoglobulins among diabetic patients in order to determine a precise and more reliable technique to predict and manage oral manifestations of the disease. Conclusion The s-IgA levels of the diabetic patients were not significantly higher than those of the control group among the studied population. In both groups, subjects with a higher number of DMFT, greater PDI scores and oral candidiasis were found to have significantly Shahla Kakoei, Bahareh Hosseini, Ali-Akbar Haghdoost, Mojgan Sanjari, Ahmad Gholamhosseinian and Vahid F. N. Afshar Clinical and Basic Research | e511 higher s-IgA levels. Among diabetic patients, significantly higher s-IgA levels were concomitant with xerostomia and denture stomatitis. Furthermore, s-IgA levels were found to be significantly elevated in patients with uncontrolled T2DM compared to those with controlled T2DM. Further research is needed to investigate s-IgA concentrations among diabetic patients in order to aid in the prediction and management of oral manifestations. a c k n o w l e d g e m e n t s This article was based on a thesis submitted to the Kerman Dental School (no. 753). The authors wish to thank the Research Committee of the Kerman University of Medical Sciences for their financial support. c o n f l i c t o f i n t e r e s t The authors declare no conflicts of interest. References 1. Mohiti-Ardekani A, Karbassi MH, Mohiti-Ardekani J, Akhondinasab F, Mohammad MH. Evaluation of salivary IgA in diabetic and non-diabetic patients: A case-control study. Iran J Diabetes Obes 2012; 4:167–71. 2. Petrou-Amerikanou C, Markopoulos AK, Belazi M, Karamitsos D, Papanayotou P. Prevalence of oral lichen planus in diabetes mellitus according to the type of diabetes. Oral Dis 1998; 4:37–40. doi: 10.1111/j.1601-0825.1998.tb00253.x. 3. Marcotte H, Lavoie MC. Oral microbial ecology and the role of salivary immunoglobulin A. Microbiol Mol Biol Rev 1998; 62:71–109. 4. Branco-de-Almeida LS, Alves CM, Lopes FF, Pereira Ade F, Guerra RN, Pereira AL. Salivary IgA and periodontal treatment needs in diabetic patients. Braz Oral Res 2011; 25:550–5. doi: 10.1590/S1806-83242011000600013. 5. Bakianian Vaziri P, Vahedi M, Mortazavi H, Abdollahzade SH, Hajilooi M. Evaluation of salivary glucose, IgA and flow rate in diabetic patients: A case-control study. J Dent (Tehran) 2010; 7:13–18. 6. Bonamico M, Nenna R, Luparia RP, Perricone C, Montuori M, Lucantoni F, et al. Radioimmunological detection of anti- transglutaminase autoantibodies in human saliva: A useful test to monitor coeliac disease follow-up. Aliment Pharmacol Ther 2008; 28:364–70. doi: 10.1111/j.1365-2036.2008.03720.x. 7. Yap G, Sil BK, Ng LC. Use of saliva for early dengue diagnosis. PLoS Negl Trop Dis 2011; 5:e1046. doi: 10.1371/journal.pntd.0001046. 8. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33:S62–9. doi: 10.2337/ dc10-S062. 9. World Health Organization. Oral health surveys: Basic methods. 3rd ed. Geneva, Switzerland: WHO Press, 1987. 10. Fox PC, Busch KA, Baum BJ. Subjective reports of xerostomia and objective measures of salivary gland performance. J Am Dent Assoc 1987; 115:581–4. doi: 10.1016/S0002-8177(87)54012-0. 11. Belazi MA, Galli-Tsinopoulou A, Drakoulakos D, Fleva A, Papanayiotou PH. Salivary alterations in insulin-dependent diabetes mellitus. Int J Paediatr Dent 1998; 8:29–33. doi: 10.1046/j.1365-263X.1998.00057.x. 12. Malicka B, Kaczmarek U, Skośkiewicz-Malinowska K. Selected antibacterial factors in the saliva of diabetic patients. Arch Oral Biol 2015; 60:425–31. doi: 10.1016/j.archoralbio.2014.07.010. 13. Parirokh M, Eghbal MJ, Ghoddusi J, Kakoei S, Haghdoost AA, Kakooei S. The frequency of medically compromised patients in endodontic offices in Iran. Iran Endod J 2013; 8:48–51. doi: 10.7508/10.7508/iej. 14. Castagnola M, Picciotti PM, Messana I, Fanali C, Fiorita A, Cabras T, et al. Potential applications of human saliva as diagnostic fluid. Acta Otorhinolaryngol Ital 2011; 31:347–57. 15. Ranadheer E, Nayak UA, Reddy NV, Rao VA. The relationship between salivary IgA levels and dental caries in children. J Indian Soc Pedod Prev Dent 2011; 29:106–12. doi: 10.4103/0970- 4388.84681. 16. Al-Maskari A, Al-Maskari M, Al-Sudairy A. Oral manifestations and complications of diabetes mellitus: A review. Sultan Qaboos Univ Med J 2011; 11:179–86. 17. Ohyama K, Moriyama M, Hayashida JN, Tanaka A, Maehara T, Ieda S, et al. Saliva as a potential tool for diagnosis of dry mouth including Sjögren’s syndrome. Oral Dis 2015; 21:224–31. doi: 10.1111/odi.12252. 18. Brito e Cabral P, Júnior JE, de Macedo AC, Alves AR, Gonçalves TB, Brito e Cabral TC, et al. Anti-PGL1 salivary IgA/IgM, serum IgG/IgM, and nasal Mycobacterium leprae DNA in individuals with household contact with leprosy. Int J Infect Dis 2013; 17:e1005–10. doi: 10.1016/j.ijid.2013.05.011. 19. Olayanju OA, Rahamon SK, Joseph IO, Arinola OG. Salivary immunoglobulin classes in Nigerians with periodontitis. J Contemp Dent Pract 2012; 13:163–6. doi: 10.5005/jp- journals-10024-1114. 20. Divya VC, Sathasivasubramanian S. Estimation of serum and salivary immunoglobulin G and immunoglobulin A in oral pre- cancer: A study in oral submucous fibrosis and oral lichen planus. J Nat Sci Biol Med 2014; 5:90–4. doi: 10.4103/0976-9668.127294. 21. Ghaleyani P, Sardari F, Akbari M. Salivary IgA and IgG in oral lichen planus and oral lichenoid reactions diseases. Adv Biomed Res 2012; 1:73. doi: 10.4103/2277-9175.102977. 22. Ben-Aryeh H, Cohen M, Kanter Y, Szargel R, Laufer D. Salivary composition in diabetic patients. J Diabet Complications 1988; 2:96–9. doi: 10.1016/0891-6632(88)90011-6. 23. Dodds MW, Yeh CK, Johnson DA. Salivary alterations in type 2 (non-insulin-dependent) diabetes mellitus and hypertension. Community Dent Oral Epidemiol 2000; 28:373–81. doi: 10.1034/j.1600-0528.2000.028005373.x. 24. Harrison R, Bowen WH. Flow rate and organic constituents of whole saliva in insulin-dependent diabetic children and adolescents. Pediatr Dent 1987; 9:287–91. 25. Kakoei S, Hosseini B, Haghdoost AA, Sanjari M, Hashemipour MA, Gholamhosseinian A. The detection of salivary glucose, caries and periodontal status in diabetes mellitus patients. J Oral Health Oral Epidemiol 2014; 3:79–84. 26. Bachrach G, Muster Z, Raz I, Chaushu G, Stabholz A, Nussbaum G, et al. Assessing the levels of immunoglobulins in the saliva of diabetic individuals with periodontitis using checkerboard immunodetection. Oral Dis 2008; 14:51–9. doi: 10.1111/j.1601- 0825.2006.01345.x. 27. López ME, Colloca ME, Páez RG, Schallmach JN, Koss MA, Chervonagura A. Salivary characteristics of diabetic children. Braz Dent J 2003; 14:26–31. doi: 10.1590/S0103-64402003000100005. 28. Jeganathan S, Ufomata D, Hobkirk JA, Ivanyi L. Immunoglobulin A1 and A2 subclass of salivary antibodies to Candida albicans in patients with oral candidosis. Clin Exp Immunol 1987; 70:316–21. 29. Popova E, Stankova G, Dermendzieva S. [Quantitative determination of immunoglobulins in serum and saliva of patients with denture stomatitis]. Stomatologiia (Sofiia) 1989; 71:23–7. 30. Wilson J, Wilton JM, Sterne JA. Comparison of secretory IgA and IgG isotype levels in palatal secretions of denture stomatitis patients with denture wearers having clinically healthy palates. Eur J Prosthodont Restor Dent 2007; 15:50–4. http://dx.doi.org/10.1111/j.1601-0825.1998.tb00253.x http://dx.doi.org/10.1590/S1806-83242011000600013 http://dx.doi.org/10.1111/j.1365-2036.2008.03720.x http://dx.doi.org/10.1371/journal.pntd.0001046 http://dx.doi.org/10.2337/dc10-S062 http://dx.doi.org/10.2337/dc10-S062 http://dx.doi.org/10.1016/S0002-8177%2887%2954012-0 http://dx.doi.org/10.1046/j.1365-263X.1998.00057.x http://dx.doi.org/10.1016/j.archoralbio.2014.07.010 http://dx.doi.org/10.7508/10.7508/iej http://dx.doi.org/10.4103/0970-4388.84681 http://dx.doi.org/10.4103/0970-4388.84681 http://dx.doi.org/10.1111/odi.12252 http://dx.doi.org/10.1016/j.ijid.2013.05.011 http://dx.doi.org/10.5005/jp-journals-10024-1114 http://dx.doi.org/10.5005/jp-journals-10024-1114 http://dx.doi.org/10.4103/0976-9668.127294 http://dx.doi.org/10.4103/2277-9175.102977 http://dx.doi.org/10.1016/0891-6632%2888%2990011-6 http://dx.doi.org/10.1034/j.1600-0528.2000.028005373.x http://dx.doi.org/10.1590/S0103-64402003000100005